IHC Scientist - Translational Pathology

Working with Us
Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us.

IHC Scientist – Translational Pathology

The successful scientist will work with colleagues throughout BMS to establish assays using immunohistochemistry, multiplex staining/imaging, in situ nucleic acid hybridization, and digital pathology. The scientist will be directly responsible for the design, development, execution, and analysis of discovery and translational tissue-based biomarker assays to interrogate target prevalence, target engagement, mechanisms of action, pharmacokinetics, pharmacodynamics, ­­and prediction of treatment response. The position entails working on projects independently and in multi-disciplinary teams consisting of pathologists, lab scientists, data scientists and clinical biomarker scientists. The IHC scientist will develop tissue-based assays for internal or external use with accountability for assays transferred to partner labs and contract research organizations (CROs). The scientist will also be responsible for working independently and with digital pathology colleagues to build and assess image analysis algorithms and workflows.

The successful scientist must have strong technical experience in IHC assay development using several platforms and techniques and a working knowledge of histology/morphology/pathology interpretation relevant to assay development.  The scientist must show strong communication and organizational skills, the ability to work collaboratively with other team members, adaptability to regulated work environments and the flexibility to accommodate changing business needs.

Required Skills/Qualifications:

• A bachelor’s degree in biological sciences or related field with minimum 5+ years industry experience
• Prior experience working in the fields of oncology and/or immuno-oncology
• Prior experience with discovery programs and exploratory assay development is desired
• Prior experience performing antibody conjugations is a plus
• Experience in monoplex and multiplex IHC assay development (chromogenic and fluorescence) with comprehension of the underlying scientific principles
• Experience with automated IHC platforms is required
• A working knowledge of histology/morphology/pathology interpretation relevant to assay development
• Ability to evaluate and onboard new technologies related to tissue-based biomarker development
• The ability to thrive and self-motivate in an interdisciplinary workplace
• The ability to clearly communicate (verbal and written) scientific objectives, logical experimental design and the analysis and interpretation of data

• Prior experience working in a regulated laboratory setting (CAP/CLIA or other GCP environment) is a plus but not necessary
• Experience with digital scanning, image management systems (IMS), and digital image analysis platforms (HALO, Visiopharm) for H&E, immunohistochemical and multiplexed fluorescence images
• Experience with in-situ nucleic acid hybridization (RNA/DNA) studies on slide-based tissue samples
• Experience with formalin-fixed paraffin-embedded workflows is required

Job description:

• Responsibility for all aspects of assay development including intake, research, planning, development, coordination, execution, risk communication/management, updates and transfer of assays including (but not limited to) chromogenic immunohistochemistry (IHC), in-situ nucleic acid hybridization, multiplexed immunofluorescence (mIF) and digital pathology

• Design, organization, and execution of assay development workflow strategies (feasibility, verification, and validation), with appropriate knowledge and